PDCD1 and cancer: Consistent with this, in a retrospective cohort study of 114 patients with cancer with a history of hepatitis B who received ICIs, 5.3% developed reactivation of hepatitis B virus.76 All six patients had undetectable viral DNA at baseline and received PD-1/PD-L1 blockade.